{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:49:25Z","timestamp":1785890965522,"version":"3.56.0"},"reference-count":88,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"vor","delay-in-days":44,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100007204","name":"Vallee Foundation","doi-asserted-by":"publisher","award":["Vallee Scholars Program"],"award-info":[{"award-number":["Vallee Scholars Program"]}],"id":[{"id":"10.13039\/100007204","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005665","name":"Kinship Foundation","doi-asserted-by":"publisher","award":["Searle Scholars Program"],"award-info":[{"award-number":["Searle Scholars Program"]}],"id":[{"id":"10.13039\/100005665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000011","name":"Howard Hughes Medical Institute","doi-asserted-by":"publisher","award":["Emerging Pathogens Initiative"],"award-info":[{"award-number":["Emerging Pathogens Initiative"]}],"id":[{"id":"10.13039\/100000011","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002920","name":"Research Grants Council, University Grants Committee","doi-asserted-by":"publisher","award":["HKU C7053-24G"],"award-info":[{"award-number":["HKU C7053-24G"]}],"id":[{"id":"10.13039\/501100002920","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Characterization of antibodies targeting the conserved stem domain of influenza hemagglutinin (HA) is critical for developing broadly protective countermeasures against the influenza virus. From a phage display human antibody library, this study discovers three group 1 HA-specific stem antibodies, namely HB31, HB34, and HB315, all of which are encoded by IGHV3-23. While HB31 and HB34 have minimal neutralization activity in vitro, their Fc-mediated effector functions lead to better in vivo protection than the potently neutralizing HB315. Consistently, cryo-EM analysis suggests that HB31 and HB34 have a higher Fc accessibility than HB315, based on their epitopes and approaching angles. HB31 and HB34 engage a pocket in the upper HA stem that is rarely targeted by known HA stem antibodies, whereas the epitope of HB315 involves the lower stem. Overall, our findings provide insights not only into the structure-function relationship of HA stem antibodies but also into the design of next-generation influenza therapeutics.<\/jats:p>","DOI":"10.1038\/s41467-026-74658-w","type":"journal-article","created":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T05:15:13Z","timestamp":1782105313000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Structural basis for distinct protective mechanisms of IGHV3-23 antibodies targeting influenza hemagglutinin stem"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2218-0076","authenticated-orcid":false,"given":"Huibin","family":"Lv","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang Wei","family":"Huan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tossapol","family":"Pholcharee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6749-9684","authenticated-orcid":false,"given":"Qi Wen","family":"Teo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenkan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akshita B.","family":"Gopal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danbi","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-6935-9226","authenticated-orcid":false,"given":"Madison R.","family":"Ardagh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5337-5357","authenticated-orcid":false,"given":"Timothy J. C.","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanxin","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arjun","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinghang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6615-9730","authenticated-orcid":false,"given":"Mateusz","family":"Szlembarski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica J.","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily X.","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas E.","family":"Wittenborn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Poorva","family":"Kasture","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0525-6772","authenticated-orcid":false,"given":"Chris K. P.","family":"Mok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9078-6697","authenticated-orcid":false,"given":"Nicholas C.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,22]]},"reference":[{"key":"74658_CR1","unstructured":"WHO. The burden of influenza. https:\/\/www.who.int\/news-room\/feature-stories\/detail\/the-burden-of-influenza (2024)."},{"key":"74658_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-024-01010-y","volume":"9","author":"IG Barr","year":"2024","unstructured":"Barr, I. G. & Subbarao, K. Implications of the apparent extinction of B\/Yamagata-lineage human influenza viruses. NPJ Vaccines 9, 219 (2024).","journal-title":"NPJ Vaccines"},{"key":"74658_CR3","doi-asserted-by":"publisher","first-page":"100851","DOI":"10.1016\/S2666-5247(24)00066-1","volume":"5","author":"S Caini","year":"2024","unstructured":"Caini, S. et al. Probable extinction of influenza B\/Yamagata and its public health implications: a systematic literature review and assessment of global surveillance databases. Lancet Microbe 5, 100851 (2024).","journal-title":"Lancet Microbe"},{"key":"74658_CR4","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1038\/s12276-021-00603-0","volume":"53","author":"WN Harrington","year":"2021","unstructured":"Harrington, W. N., Kackos, C. M. & Webby, R. J. The evolution and future of influenza pandemic preparedness. Exp. Mol. Med. 53, 737\u2013749 (2021).","journal-title":"Exp. Mol. Med."},{"key":"74658_CR5","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/S1473-3099(13)70167-1","volume":"13","author":"KK To","year":"2013","unstructured":"To, K. K., Chan, J. F., Chen, H., Li, L. & Yuen, K. Y. The emergence of influenza A H7N9 in human beings 16 years after influenza A H5N1: a tale of two cities. Lancet Infect. Dis. 13, 809\u2013821 (2013).","journal-title":"Lancet Infect. Dis."},{"key":"74658_CR6","doi-asserted-by":"publisher","first-page":"eadq0900","DOI":"10.1126\/science.adq0900","volume":"388","author":"TQ Nguyen","year":"2025","unstructured":"Nguyen, T. Q. et al. Emergence and interstate spread of highly pathogenic avian influenza A(H5N1) in dairy cattle in the United States. Science 388, eadq0900 (2025).","journal-title":"Science"},{"key":"74658_CR7","doi-asserted-by":"publisher","unstructured":"Basilio, H. Bird-flu vaccine for cattle aces early test. Nature https:\/\/doi.org\/10.1038\/d41586-025-01497-y (2025).","DOI":"10.1038\/d41586-025-01497-y"},{"key":"74658_CR8","unstructured":"CDC. H5 bird flu: Current situation. https:\/\/www.cdc.gov\/bird-flu\/situation-summary\/index.html (2026)."},{"key":"74658_CR9","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/s41577-019-0143-6","volume":"19","author":"F Krammer","year":"2019","unstructured":"Krammer, F. The human antibody response to influenza A virus infection and vaccination. Nat. Rev. Immunol. 19, 383\u2013397 (2019).","journal-title":"Nat. Rev. Immunol."},{"key":"74658_CR10","doi-asserted-by":"publisher","first-page":"a038778","DOI":"10.1101\/cshperspect.a038778","volume":"10","author":"NC Wu","year":"2020","unstructured":"Wu, N. C. & Wilson, I. A. Influenza hemagglutinin structures and antibody recognition. Cold Spring Harb. Perspect. Med 10, a038778 (2020).","journal-title":"Cold Spring Harb. Perspect. Med"},{"key":"74658_CR11","doi-asserted-by":"publisher","first-page":"2694","DOI":"10.1016\/j.jmb.2017.06.015","volume":"429","author":"NC Wu","year":"2017","unstructured":"Wu, N. C. & Wilson, I. A. A perspective on the structural and functional constraints for immune evasion: insights from influenza virus. J. Mol. Biol. 429, 2694\u20132709 (2017).","journal-title":"J. Mol. Biol."},{"key":"74658_CR12","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1126\/science.1222908","volume":"337","author":"C Dreyfus","year":"2012","unstructured":"Dreyfus, C. et al. Highly conserved protective epitopes on influenza B viruses. Science 337, 1343\u20131348 (2012).","journal-title":"Science"},{"key":"74658_CR13","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.cell.2016.05.073","volume":"166","author":"NL Kallewaard","year":"2016","unstructured":"Kallewaard, N. L. et al. Structure and function analysis of an antibody recognizing all influenza A subtypes. Cell 166, 596\u2013608 (2016).","journal-title":"Cell"},{"key":"74658_CR14","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1126\/science.1205669","volume":"333","author":"D Corti","year":"2011","unstructured":"Corti, D. et al. A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science 333, 850\u2013856 (2011).","journal-title":"Science"},{"key":"74658_CR15","doi-asserted-by":"publisher","first-page":"eaan2676","DOI":"10.1126\/sciimmunol.aan2676","volume":"2","author":"SF Andrews","year":"2017","unstructured":"Andrews, S. F. et al. Preferential induction of cross-group influenza A hemagglutinin stem-specific memory B cells after H7N9 immunization in humans. Sci. Immunol. 2, eaan2676 (2017).","journal-title":"Sci. Immunol."},{"key":"74658_CR16","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1126\/science.1204839","volume":"333","author":"DC Ekiert","year":"2011","unstructured":"Ekiert, D. C. et al. A highly conserved neutralizing epitope on group 2 influenza A viruses. Science 333, 843\u2013850 (2011).","journal-title":"Science"},{"key":"74658_CR17","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1073\/pnas.1319058110","volume":"111","author":"RH Friesen","year":"2014","unstructured":"Friesen, R. H. et al. A common solution to group 2 influenza virus neutralization. Proc. Natl. Acad. Sci. USA 111, 445\u2013450 (2014).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"74658_CR18","doi-asserted-by":"publisher","first-page":"2935","DOI":"10.1016\/j.celrep.2017.08.084","volume":"20","author":"S Lang","year":"2017","unstructured":"Lang, S. et al. Antibody 27F3 broadly targets influenza A group 1 and 2 hemagglutinins through a further variation in VH1-69 antibody orientation on the HA stem. Cell Rep. 20, 2935\u20132943 (2017).","journal-title":"Cell Rep."},{"key":"74658_CR19","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.cell.2016.06.043","volume":"166","author":"MG Joyce","year":"2016","unstructured":"Joyce, M. G. et al. Vaccine-induced antibodies that neutralize group 1 and group 2 influenza A viruses. Cell 166, 609\u2013623 (2016).","journal-title":"Cell"},{"key":"74658_CR20","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.chom.2020.06.003","volume":"28","author":"NC Wu","year":"2020","unstructured":"Wu, N. C. et al. Convergent evolution in breadth of two VH6-1-encoded influenza antibody clonotypes from a single donor. Cell Host Microbe 28, 434\u2013444 (2020).","journal-title":"Cell Host Microbe"},{"key":"74658_CR21","doi-asserted-by":"publisher","first-page":"662909","DOI":"10.3389\/fimmu.2021.662909","volume":"12","author":"GY Chuang","year":"2021","unstructured":"Chuang, G. Y. et al. Sequence-signature optimization enables improved identification of human HV6-1-derived class antibodies that neutralize diverse influenza A viruses. Front Immunol. 12, 662909 (2021).","journal-title":"Front Immunol."},{"key":"74658_CR22","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.chom.2018.09.010","volume":"24","author":"NC Wu","year":"2018","unstructured":"Wu, N. C. et al. Recurring and adaptable binding motifs in broadly neutralizing antibodies to influenza virus are encoded on the D3-9 segment of the Ig gene. Cell Host Microbe 24, 569\u2013578.e4 (2018).","journal-title":"Cell Host Microbe"},{"key":"74658_CR23","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1016\/j.immuni.2024.07.022","volume":"57","author":"Y Wang","year":"2024","unstructured":"Wang, Y. et al. An explainable language model for antibody specificity prediction using curated influenza hemagglutinin antibodies. Immunity 57, 2453\u20132465.e7 (2024).","journal-title":"Immunity"},{"key":"74658_CR24","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1126\/science.1171491","volume":"324","author":"DC Ekiert","year":"2009","unstructured":"Ekiert, D. C. et al. Antibody recognition of a highly conserved influenza virus epitope. Science 324, 246\u2013251 (2009).","journal-title":"Science"},{"key":"74658_CR25","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/s41591-021-01636-8","volume":"28","author":"SF Andrews","year":"2022","unstructured":"Andrews, S. F. et al. A single residue in influenza virus H2 hemagglutinin enhances the breadth of the B cell response elicited by H2 vaccination. Nat. Med 28, 373\u2013382 (2022).","journal-title":"Nat. Med"},{"key":"74658_CR26","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1016\/j.immuni.2022.07.006","volume":"55","author":"M Sangesland","year":"2022","unstructured":"Sangesland, M. et al. Allelic polymorphism controls autoreactivity and vaccine elicitation of human broadly neutralizing antibodies against influenza virus. Immunity 55, 1693\u20131709.e8 (2022).","journal-title":"Immunity"},{"key":"74658_CR27","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1038\/s41586-021-04356-8","volume":"602","author":"JJ Guthmiller","year":"2022","unstructured":"Guthmiller, J. J. et al. Broadly neutralizing antibodies target a haemagglutinin anchor epitope. Nature 602, 314\u2013320 (2022).","journal-title":"Nature"},{"key":"74658_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-56496-4","volume":"16","author":"TH Lin","year":"2025","unstructured":"Lin, T. H. et al. Structurally convergent antibodies derived from different vaccine strategies target the influenza virus HA anchor epitope with a subset of V(H)3 and V(K)3 genes. Nat. Commun. 16, 1268 (2025).","journal-title":"Nat. Commun."},{"key":"74658_CR29","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1126\/science.aan0516","volume":"358","author":"RU Kadam","year":"2017","unstructured":"Kadam, R. U. et al. Potent peptidic fusion inhibitors of influenza virus. Science 358, 496\u2013502 (2017).","journal-title":"Science"},{"key":"74658_CR30","doi-asserted-by":"publisher","first-page":"6542","DOI":"10.1128\/JVI.00641-13","volume":"87","author":"F Krammer","year":"2013","unstructured":"Krammer, F., Pica, N., Hai, R., Margine, I. & Palese, P. Chimeric hemagglutinin influenza virus vaccine constructs elicit broadly protective stalk-specific antibodies. J. Virol. 87, 6542\u20136550 (2013).","journal-title":"J. Virol."},{"key":"74658_CR31","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1038\/nm.3927","volume":"21","author":"HM Yassine","year":"2015","unstructured":"Yassine, H. M. et al. Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection. Nat. Med. 21, 1065\u20131070 (2015).","journal-title":"Nat. Med."},{"key":"74658_CR32","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1126\/science.aac7263","volume":"349","author":"A Impagliazzo","year":"2015","unstructured":"Impagliazzo, A. et al. A stable trimeric influenza hemagglutinin stem as a broadly protective immunogen. Science 349, 1301\u20131306 (2015).","journal-title":"Science"},{"key":"74658_CR33","doi-asserted-by":"publisher","first-page":"eade4790","DOI":"10.1126\/scitranslmed.ade4790","volume":"15","author":"AT Widge","year":"2023","unstructured":"Widge, A. T. et al. An influenza hemagglutinin stem nanoparticle vaccine induces cross-group 1 neutralizing antibodies in healthy adults. Sci. Transl. Med. 15, eade4790 (2023).","journal-title":"Sci. Transl. Med."},{"key":"74658_CR34","doi-asserted-by":"publisher","first-page":"eade4976","DOI":"10.1126\/scitranslmed.ade4976","volume":"15","author":"SF Andrews","year":"2023","unstructured":"Andrews, S. F. et al. An influenza H1 hemagglutinin stem-only immunogen elicits a broadly cross-reactive B cell response in humans. Sci. Transl. Med. 15, eade4976 (2023).","journal-title":"Sci. Transl. Med."},{"key":"74658_CR35","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/s41591-020-1118-7","volume":"27","author":"R Nachbagauer","year":"2021","unstructured":"Nachbagauer, R. et al. A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trial. Nat. Med. 27, 106\u2013114 (2021).","journal-title":"Nat. Med."},{"key":"74658_CR36","doi-asserted-by":"publisher","first-page":"eadr8373","DOI":"10.1126\/scitranslmed.adr8373","volume":"17","author":"GE Mantus","year":"2025","unstructured":"Mantus, G. E. et al. Vaccination with different group 2 influenza subtypes alters epitope targeting and breadth of hemagglutinin stem-specific human B cells. Sci. Transl. Med. 17, eadr8373 (2025).","journal-title":"Sci. Transl. Med."},{"key":"74658_CR37","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1126\/science.1202617","volume":"332","author":"SJ Fleishman","year":"2011","unstructured":"Fleishman, S. J. et al. Computational design of proteins targeting the conserved stem region of influenza hemagglutinin. Science 332, 816\u2013821 (2011).","journal-title":"Science"},{"key":"74658_CR38","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/nbt.2214","volume":"30","author":"TA Whitehead","year":"2012","unstructured":"Whitehead, T. A. et al. Optimization of affinity, specificity and function of designed influenza inhibitors using deep sequencing. Nat. Biotechnol. 30, 543\u2013548 (2012).","journal-title":"Nat. Biotechnol."},{"key":"74658_CR39","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/nature23912","volume":"550","author":"A Chevalier","year":"2017","unstructured":"Chevalier, A. et al. Massively parallel de novo protein design for targeted therapeutics. Nature 550, 74\u201379 (2017).","journal-title":"Nature"},{"key":"74658_CR40","doi-asserted-by":"publisher","first-page":"e1005409","DOI":"10.1371\/journal.ppat.1005409","volume":"12","author":"MT Koday","year":"2016","unstructured":"Koday, M. T. et al. A computationally designed hemagglutinin stem-binding protein provides in vivo protection from influenza independent of a host immune response. PLoS Pathog. 12, e1005409 (2016).","journal-title":"PLoS Pathog."},{"key":"74658_CR41","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1038\/s41586-025-09721-5","volume":"649","author":"NR Bennett","year":"2026","unstructured":"Bennett, N. R. et al. Atomically accurate de novo design of antibodies with RFdiffusion. Nature 649, 183\u2013193 (2026).","journal-title":"Nature"},{"key":"74658_CR42","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1021\/acschembio.2c00040","volume":"17","author":"MN Pascha","year":"2022","unstructured":"Pascha, M. N. et al. Inhibition of H1 and H5 influenza A virus entry by diverse macrocyclic peptides targeting the hemagglutinin stem region. ACS Chem. Biol. 17, 2425\u20132436 (2022).","journal-title":"ACS Chem. Biol."},{"key":"74658_CR43","doi-asserted-by":"publisher","first-page":"e2310677121","DOI":"10.1073\/pnas.2310677121","volume":"121","author":"S Kitamura","year":"2024","unstructured":"Kitamura, S. et al. Ultrapotent influenza hemagglutinin fusion inhibitors developed through SuFEx-enabled high-throughput medicinal chemistry. Proc. Natl. Acad. Sci. USA 121, e2310677121 (2024).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"74658_CR44","doi-asserted-by":"publisher","first-page":"eaar6221","DOI":"10.1126\/science.aar6221","volume":"363","author":"MJP van Dongen","year":"2019","unstructured":"van Dongen, M. J. P. et al. A small-molecule fusion inhibitor of influenza virus is orally active in mice. Science 363, eaar6221 (2019).","journal-title":"Science"},{"key":"74658_CR45","doi-asserted-by":"publisher","first-page":"18431","DOI":"10.1073\/pnas.2006893117","volume":"117","author":"Y Yao","year":"2020","unstructured":"Yao, Y. et al. An influenza A hemagglutinin small-molecule fusion inhibitor identified by a new high-throughput fluorescence polarization screen. Proc. Natl. Acad. Sci. USA 117, 18431\u201318438 (2020).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"74658_CR46","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1016\/j.chom.2025.09.015","volume":"33","author":"H Lv","year":"2025","unstructured":"Lv, H. et al. Evolution of antibody cross-reactivity to influenza H5N1 neuraminidase from an N2-specific germline. Cell Host Microbe 33, 1916\u20131928.e6 (2025).","journal-title":"Cell Host Microbe"},{"key":"74658_CR47","doi-asserted-by":"publisher","first-page":"e02810","DOI":"10.1128\/mBio.02810-18","volume":"10","author":"KS Corbett","year":"2019","unstructured":"Corbett, K. S. et al. Design of nanoparticulate group 2 influenza virus hemagglutinin stem antigens that activate unmutated ancestor B cell receptors of broadly neutralizing antibody lineages. mBio 10, e02810\u2013e02818 (2019).","journal-title":"mBio"},{"key":"74658_CR48","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1016\/j.chom.2016.05.014","volume":"19","author":"CJ Henry Dunand","year":"2016","unstructured":"Henry Dunand, C. J. et al. Both neutralizing and non-neutralizing human H7N9 influenza vaccine-induced monoclonal antibodies confer protection. Cell Host Microbe 19, 800\u2013813 (2016).","journal-title":"Cell Host Microbe"},{"key":"74658_CR49","doi-asserted-by":"publisher","first-page":"e01603","DOI":"10.1128\/JVI.01603-17","volume":"91","author":"TC Sutton","year":"2017","unstructured":"Sutton, T. C. et al. In vitro neutralization is not predictive of prophylactic efficacy of broadly neutralizing monoclonal antibodies CR6261 and CR9114 against lethal H2 influenza virus challenge in mice. J. Virol. 91, e01603\u2013e01617 (2017).","journal-title":"J. Virol."},{"key":"74658_CR50","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1172\/JCI84428","volume":"126","author":"DJ DiLillo","year":"2016","unstructured":"DiLillo, D. J., Palese, P., Wilson, P. C. & Ravetch, J. V. Broadly neutralizing anti-influenza antibodies require Fc receptor engagement for in vivo protection. J. Clin. Invest 126, 605\u2013610 (2016).","journal-title":"J. Clin. Invest"},{"key":"74658_CR51","doi-asserted-by":"publisher","first-page":"3900","DOI":"10.1074\/jbc.M116.767749","volume":"292","author":"M Lo","year":"2017","unstructured":"Lo, M. et al. Effector-attenuating substitutions that maintain antibody stability and reduce toxicity in mice. J. Biol. Chem. 292, 3900\u20133908 (2017).","journal-title":"J. Biol. Chem."},{"key":"74658_CR52","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1126\/science.aaz5143","volume":"368","author":"NC Wu","year":"2020","unstructured":"Wu, N. C. et al. Different genetic barriers for resistance to HA stem antibodies in influenza H3 and H1 viruses. Science 368, 1335\u20131340 (2020).","journal-title":"Science"},{"key":"74658_CR53","doi-asserted-by":"publisher","first-page":"e20240668","DOI":"10.1084\/jem.20240668","volume":"221","author":"KM McIntire","year":"2024","unstructured":"McIntire, K. M. et al. Maturation of germinal center B cells after influenza virus vaccination in humans. J. Exp. Med. 221, e20240668 (2024).","journal-title":"J. Exp. Med."},{"key":"74658_CR54","doi-asserted-by":"publisher","first-page":"10112","DOI":"10.1073\/pnas.1810927115","volume":"115","author":"DJ Benton","year":"2018","unstructured":"Benton, D. J. et al. Influenza hemagglutinin membrane anchor. Proc. Natl. Acad. Sci. USA 115, 10112\u201310117 (2018).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"74658_CR55","doi-asserted-by":"publisher","first-page":"114990","DOI":"10.1016\/j.celrep.2024.114990","volume":"43","author":"S Ataca","year":"2024","unstructured":"Ataca, S. et al. Modulating the immunodominance hierarchy of immunoglobulin germline-encoded structural motifs targeting the influenza hemagglutinin stem. Cell Rep. 43, 114990 (2024).","journal-title":"Cell Rep."},{"key":"74658_CR56","doi-asserted-by":"publisher","first-page":"467","DOI":"10.3390\/vaccines12050467","volume":"12","author":"M Yuan","year":"2024","unstructured":"Yuan, M. & Wilson, I. A. The D gene in CDR H3 determines a public class of human antibodies to SARS-CoV-2. Vaccines 12, 467 (2024).","journal-title":"Vaccines"},{"key":"74658_CR57","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1016\/j.immuni.2022.03.019","volume":"55","author":"Y Wang","year":"2022","unstructured":"Wang, Y. et al. A large-scale systematic survey reveals recurring molecular features of public antibody responses to SARS-CoV-2. Immunity 55, 1105\u20131117.e4 (2022).","journal-title":"Immunity"},{"key":"74658_CR58","doi-asserted-by":"publisher","first-page":"e1013086","DOI":"10.1371\/journal.ppat.1013086","volume":"21","author":"JJ Carter","year":"2025","unstructured":"Carter, J. J. et al. Human monoclonal antibodies to HPV16 show evidence for common developmental pathways and public epitopes. PLoS Pathog. 21, e1013086 (2025).","journal-title":"PLoS Pathog."},{"key":"74658_CR59","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/j.cell.2017.06.048","volume":"170","author":"JA Horwitz","year":"2017","unstructured":"Horwitz, J. A. et al. Non-neutralizing antibodies alter the course of HIV-1 infection in vivo. Cell 170, 637\u2013648.e10 (2017).","journal-title":"Cell"},{"key":"74658_CR60","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.3389\/fimmu.2017.01590","volume":"8","author":"LM Mayr","year":"2017","unstructured":"Mayr, L. M., Su, B. & Moog, C. Non-neutralizing antibodies directed against HIV and their functions. Front Immunol. 8, 1590 (2017).","journal-title":"Front Immunol."},{"key":"74658_CR61","doi-asserted-by":"publisher","first-page":"e1011569","DOI":"10.1371\/journal.ppat.1011569","volume":"20","author":"CN Pierre","year":"2024","unstructured":"Pierre, C. N. et al. Non-neutralizing SARS-CoV-2 N-terminal domain antibodies protect mice against severe disease using Fc-mediated effector functions. PLoS Pathog. 20, e1011569 (2024).","journal-title":"PLoS Pathog."},{"key":"74658_CR62","doi-asserted-by":"publisher","first-page":"114922","DOI":"10.1016\/j.celrep.2024.114922","volume":"43","author":"JJ Clark","year":"2024","unstructured":"Clark, J. J. et al. Protective effect and molecular mechanisms of human non-neutralizing cross-reactive spike antibodies elicited by SARS-CoV-2 mRNA vaccination. Cell Rep. 43, 114922 (2024).","journal-title":"Cell Rep."},{"key":"74658_CR63","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-07008-0","volume":"9","author":"MJ Bailey","year":"2018","unstructured":"Bailey, M. J. et al. Human antibodies targeting Zika virus NS1 provide protection against disease in a mouse model. Nat. Commun. 9, 4560 (2018).","journal-title":"Nat. Commun."},{"key":"74658_CR64","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/j.chom.2020.03.025","volume":"27","author":"PA Ilinykh","year":"2020","unstructured":"Ilinykh, P. A. et al. Non-neutralizing antibodies from a Marburg infection survivor mediate protection by Fc-effector functions and by enhancing efficacy of other antibodies. Cell Host Microbe 27, 976\u2013991.e11 (2020).","journal-title":"Cell Host Microbe"},{"key":"74658_CR65","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1128\/JVI.80.3.1340-1351.2006","volume":"80","author":"KM Chung","year":"2006","unstructured":"Chung, K. M. et al. Antibodies against West Nile Virus nonstructural protein NS1 prevent lethal infection through Fc gamma receptor-dependent and -independent mechanisms. J. Virol. 80, 1340\u20131351 (2006).","journal-title":"J. Virol."},{"key":"74658_CR66","doi-asserted-by":"publisher","first-page":"eaaw9535","DOI":"10.1126\/sciadv.aaw9535","volume":"5","author":"JW Golden","year":"2019","unstructured":"Golden, J. W. et al. GP38-targeting monoclonal antibodies protect adult mice against lethal Crimean-Congo hemorrhagic fever virus infection. Sci. Adv. 5, eaaw9535 (2019).","journal-title":"Sci. Adv."},{"key":"74658_CR67","doi-asserted-by":"publisher","first-page":"115331","DOI":"10.1016\/j.celrep.2025.115331","volume":"44","author":"MV Bick","year":"2025","unstructured":"Bick, M. V. et al. Molecular parameters governing antibody FcgammaR signaling and effector functions in the context of HIV envelope. Cell Rep. 44, 115331 (2025).","journal-title":"Cell Rep."},{"key":"74658_CR68","doi-asserted-by":"crossref","unstructured":"US government slams mRNA vaccine research. Nat. Biotechnol. 43, 1400 (2025).","DOI":"10.1038\/s41587-025-02826-2"},{"key":"74658_CR69","doi-asserted-by":"publisher","first-page":"101226","DOI":"10.1016\/j.lanmic.2025.101226","volume":"6","author":"E Petersen","year":"2025","unstructured":"Petersen, E. et al. Protecting the future of vaccine development amidst US funding withdrawal for mRNA vaccine research. Lancet Microbe 6, 101226 (2025).","journal-title":"Lancet Microbe"},{"key":"74658_CR70","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1038\/s41586-020-2622-0","volume":"586","author":"KS Corbett","year":"2020","unstructured":"Corbett, K. S. et al. SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Nature 586, 567\u2013571 (2020).","journal-title":"Nature"},{"key":"74658_CR71","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","volume":"383","author":"FP Polack","year":"2020","unstructured":"Polack, F. P. et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N. Engl. J. Med. 383, 2603\u20132615 (2020).","journal-title":"N. Engl. J. Med."},{"key":"74658_CR72","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/s41594-018-0025-9","volume":"25","author":"NC Wu","year":"2018","unstructured":"Wu, N. C. & Wilson, I. A. Structural insights into the design of novel anti-influenza therapies. Nat. Struct. Mol. Biol. 25, 115\u2013121 (2018).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"74658_CR73","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/978-1-4939-8958-4_5","volume":"1904","author":"JJ Guthmiller","year":"2019","unstructured":"Guthmiller, J. J., Dugan, H. L., Neu, K. E., Lan, L. Y. & Wilson, P. C. An efficient method to generate monoclonal antibodies from human B cells. Methods Mol. Biol. 1904, 109\u2013145 (2019).","journal-title":"Methods Mol. Biol."},{"key":"74658_CR74","doi-asserted-by":"publisher","first-page":"113410","DOI":"10.1016\/j.celrep.2023.113410","volume":"42","author":"QW Teo","year":"2023","unstructured":"Teo, Q. W. et al. Stringent and complex sequence constraints of an IGHV1-69 broadly neutralizing antibody to influenza HA stem. Cell Rep. 42, 113410 (2023).","journal-title":"Cell Rep."},{"key":"74658_CR75","doi-asserted-by":"publisher","first-page":"6108","DOI":"10.1073\/pnas.100133697","volume":"97","author":"E Hoffmann","year":"2000","unstructured":"Hoffmann, E., Neumann, G., Kawaoka, Y., Hobom, G. & Webster, R. G. A DNA transfection system for generation of influenza A virus from eight plasmids. Proc. Natl. Acad. Sci. USA 97, 6108\u20136113 (2000).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"74658_CR76","doi-asserted-by":"publisher","first-page":"e0169524","DOI":"10.1128\/jvi.01695-24","volume":"99","author":"H Lv","year":"2025","unstructured":"Lv, H. et al. Differential antigenic imprinting effects between influenza H1N1 hemagglutinin and neuraminidase in a mouse model. J. Virol. 99, e0169524 (2025).","journal-title":"J. Virol."},{"key":"74658_CR77","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/nmeth.4169","volume":"14","author":"A Punjani","year":"2017","unstructured":"Punjani, A., Rubinstein, J. L., Fleet, D. J. & Brubaker, M. A. cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination. Nat. Methods 14, 290\u2013296 (2017).","journal-title":"Nat. Methods"},{"key":"74658_CR78","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1038\/s42003-021-02399-1","volume":"4","author":"R Sanchez-Garcia","year":"2021","unstructured":"Sanchez-Garcia, R. et al. DeepEMhancer: a deep learning solution for cryo-EM volume post-processing. Commun. Biol. 4, 874 (2021).","journal-title":"Commun. Biol."},{"key":"74658_CR79","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/s41586-024-07215-4","volume":"628","author":"K Jamali","year":"2024","unstructured":"Jamali, K. et al. Automated model building and protein identification in cryo-EM maps. Nature 628, 450\u2013457 (2024).","journal-title":"Nature"},{"key":"74658_CR80","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1002\/pro.3791","volume":"29","author":"A Casanal","year":"2020","unstructured":"Casanal, A., Lohkamp, B. & Emsley, P. Current developments in Coot for macromolecular model building of electron cryo-microscopy and crystallographic data. Protein Sci. 29, 1069\u20131078 (2020).","journal-title":"Protein Sci."},{"key":"74658_CR81","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1107\/S2059798318006551","volume":"74","author":"PV Afonine","year":"2018","unstructured":"Afonine, P. V. et al. Real-space refinement in PHENIX for cryo-EM and crystallography. Acta Crystallogr D. Struct. Biol. 74, 531\u2013544 (2018).","journal-title":"Acta Crystallogr D. Struct. Biol."},{"key":"74658_CR82","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/j.jmb.2007.05.022","volume":"372","author":"E Krissinel","year":"2007","unstructured":"Krissinel, E. & Henrick, K. Inference of macromolecular assemblies from crystalline state. J. Mol. Biol. 372, 774\u2013797 (2007).","journal-title":"J. Mol. Biol."},{"key":"74658_CR83","doi-asserted-by":"publisher","first-page":"30494","DOI":"10.2807\/1560-7917.ES.2017.22.13.30494","volume":"22","author":"Y Shu","year":"2017","unstructured":"Shu, Y. & McCauley, J. GISAID: Global initiative on sharing all influenza data - from vision to reality. Eur. Surveill. 22, 30494 (2017).","journal-title":"Eur. Surveill."},{"key":"74658_CR84","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1093\/molbev\/mst010","volume":"30","author":"K Katoh","year":"2013","unstructured":"Katoh, K. & Standley, D. M. MAFFT multiple sequence alignment software version 7: improvements in performance and usability. Mol. Biol. Evol. 30, 772\u2013780 (2013).","journal-title":"Mol. Biol. Evol."},{"key":"74658_CR85","doi-asserted-by":"publisher","first-page":"2272","DOI":"10.1093\/bioinformatics\/btz921","volume":"36","author":"A Tareen","year":"2020","unstructured":"Tareen, A. & Kinney, J. B. Logomaker: beautiful sequence logos in Python. Bioinformatics 36, 2272\u20132274 (2020).","journal-title":"Bioinformatics"},{"key":"74658_CR86","doi-asserted-by":"publisher","unstructured":"Liu, W. & Wu, N. C. For publication. https:\/\/doi.org\/10.5281\/zenodo.20435344 (2026).","DOI":"10.5281\/zenodo.20435344"},{"key":"74658_CR87","doi-asserted-by":"publisher","first-page":"3430","DOI":"10.4049\/jimmunol.1200356","volume":"189","author":"MB Overdijk","year":"2012","unstructured":"Overdijk, M. B. et al. Crosstalk between human IgG isotypes and murine effector cells. J. Immunol. 189, 3430\u20133438 (2012).","journal-title":"J. Immunol."},{"key":"74658_CR88","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1080\/19420862.2017.1323159","volume":"9","author":"G Dekkers","year":"2017","unstructured":"Dekkers, G. et al. Affinity of human IgG subclasses to mouse Fc gamma receptors. mAbs 9, 767\u2013773 (2017).","journal-title":"mAbs"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-74658-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-74658-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-74658-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:07:41Z","timestamp":1785888461000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-74658-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,22]]},"references-count":88,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["74658"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-74658-w","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,22]]},"assertion":[{"value":"6 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"N.C.W. consults for HeliXon. The authors declare no other competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"7822"}}